The authors caution that these benefits must be weighed against risk of toxicity, but, overall, the study shows promising results that warrant larger studies and efforts to identify patients most likely to benefit from this treatment. Their findings are published in"There are very few effective treatments for patients with. Our overarching objective is to find improved therapies for this patient population," said corresponding author Priscilla K.
The primary endpoint of the study was response rate, including complete response, partial response, or stable disease. Patients in the trial had primary tumor diagnoses that included breast, melanoma, non-small cell lung, small-cell lung, pituitary, and other cancers.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Gene engineered cell therapy developed to target brain metastatic melanomasOverall survival for patients with melanoma that has spread to the brain is only four to six months. Immunotherapies, which harness the power of the immune system to attack cancer cells, have garnered excitement in recent years for their potential to revolutionize the treatment of metastatic melanomas, but results from early clinical studies indicate that the prognosis for most patients remains poor. Now, scientists from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, have integrated multiple therapeutic approaches to more effectively target melanoma in the brain. In preclinical studies, the scientists successfully activated immune responses in sophisticated mouse models that mimic human settings. Findings are published in Science Translational Medicine.
Source: medical_xpress - 🏆 101. / 51 Read more »